Budget Impact Analysis of Panobinostat – Bortezomib and Dexamethasone, As 3rd Or 4th Line of Treatment in Patients with Relapsed/Refractory Multiple Myeloma in Greece
Abstract
Authors
K Vellopoulou G Kourlaba S Delimpasi M Chatzikou E Katodritou K Konstantopoulou K Megalakaki A Pouli P Repousis E Terpos